The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor expression of cGAS, not STING, negatively impacts on the efficacy of PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS ≥50.
 
Yuichi Ozawa
Honoraria - AstraZeneca; Chugai Pharma; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
 
Yuhei Harutani
Honoraria - Bristol-Myers Squibb
 
Jun Oyanagi
No Relationships to Disclose
 
Hiroaki Akamatsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - MSD (Inst)
 
Eriko Murakami
No Relationships to Disclose
 
Ryota Shibaki
No Relationships to Disclose
 
Atsushi Hayata
No Relationships to Disclose
 
Takeya Sugimoto
No Relationships to Disclose
 
Koichi Sato
No Relationships to Disclose
 
Shunsuke Teraoka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Yuka Kitamura
Employment - N Lab Co., Ltd
Leadership - N Lab Co., Ltd
Stock and Other Ownership Interests - N Lab Co., Ltd
 
Junya Fukuoka
No Relationships to Disclose
 
Nahomi Tokudome
Honoraria - Chugai Pharma; Novartis
 
Hiroki Ueda
No Relationships to Disclose
 
Masanori Nakanishi
No Relationships to Disclose
 
Yasuhiro Koh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Guardant Health; Hitachi; Pfizer; Tosoh Corporation
Consulting or Advisory Role - Takeda; Tosoh Corporation
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; On-chip Biotechnologies; TERUMO; Toppan Printing Co.; Tosoh Corporation
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Life Technologies; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Lilly (Inst); Maruho (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Toppan Printing Co. (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)